PHARMAC is proposing to fund pegfilgrastim (Neulastim) for the prevention of neutropenia in patients undergoing cancer chemotherapy, and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis. Closed: Monday, 29 April 2013.
Proposal to widen access to adalimumab for juvenile idiopathic arthritis and for fistulising Crohn’s disease
PHARMAC is seeking feedback on a proposal to widen access to adalimumab (Humira and HumiraPen) to include juvenile idiopathic arthritis and fistulising Crohns disease, and to list a 20 mg strength of Humira, from 1 July 2013. Closed: Monday, 29 April 2013.
PHARMAC has entered into provisional agreements with AFT Pharmaceuticals Ltd and Alcon New Zealand Limited for a range of eye drops. Closed: Monday, 29 April 2013.
UPDATED: PHARMAC is seeking feedback on a proposal to amend the restrictions applying to certain pharmaceuticals in the Infections - Agents for Systemic Use Group in Section B and Part II of Section H of the Pharmaceutical Schedule. Closed: Thursday, 18 April 2013.
PHARMAC is seeking feedback on a proposal to fund the antiplatelet agent ticagrelor (Brilinta). Closed: Friday, 12 April 2013.
Closed: 5 April 2013.
Proposals to list glyceryl trinitrate ointment (Rectogesic) for chronic anal fissure and to apply reference pricing across brands of lignocaine 1% injections
Closed: Tuesday, 12 February 2012
PHARMAC has entered into a provisional agreement for the funding and supply of 11 pharmaceuticals that do not have Medsafe consent (i.e. are not approved/registered). Closed: Friday, 1 February 2013.
Closed: Friday, 21 December 2012.
Proposal to fund capsaicin cream, atenolol oral liquid and bosentan and to amend the listing of erythromycin lactobionate IV